Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | MAP3K11 | Q16584 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | LITAF | Q99732 | 1/20 | 0.39 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21273193 | 0.90 | USP7 (0.48) | CYP2C9SRCUSP7MAPTPKM | |
| SCHEMBL21273091 | 0.80 | PARP1 (0.49) | KMT2AMAPTALDH1A1 | |
| SCHEMBL21272834 | 0.78 | PARP1 (0.47) | KMT2AMAPTALDH1A1 | |
| SCHEMBL21273055 | 0.78 | PARP1 (0.39) | KMT2AGAALMNAMAPTALDH1A1 | |
| SCHEMBL20971266 | 0.78 | ALDH1A1 (0.50) | SRCKMT2AMAPK1LMNAMAPT | |
| SCHEMBL19692092 | 0.78 | SRC (0.43) | CYP2C9BRD9SRCMAP3K11KMT2A | |
| SCHEMBL21273152 | 0.77 | ENPP1 (0.41) | CYP2C9BRD9KMT2AGAAMAPK1 | |
| SCHEMBL21272804 | 0.75 | PIM1 (0.43) | KMT2AGAAUSP7LMNAMAPT | |
| SCHEMBL23754625 | 0.74 | PIK3CD (0.37) | KMT2AUSP7ALDH1A1 | |
| SCHEMBL23754618 | 0.74 | CYP11B2 (0.41) | USP7MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4026832-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | Almac Discovery Limited (GB) | 2022-07-13 | — | — | EP | disclosed |
| US-10766903-B2 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | ALMAC DISCOVERY LIMITED (GB) | 2020-09-08 | — | — | US | disclosed |
| US-20190256518-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | GENETECH, INC. | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256518-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 | USP7, USP5, UBA7 | CYP2C9 4240/4885BRD9 710/4885SRC 4165/4885 |
| US-10766903-B2 | Piperidine derivatives as inhibitors of ubiquitin specific protease 7 | USP7, USP5, UBA7 | CYP2C9 4240/4885BRD9 710/4885SRC 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.